Kairos PharmaKAPA +7.49%15 FCF Yield % is -45.79 as of Jun. 30, 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 1,415 Biotechnology companies, Kairos Pharma ranks worse than 83.18% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Kairos Pharma FCF Yield % Related Terms
Kairos Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for Kairos Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kairos Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kairos Pharma FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kairos Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Kairos Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kairos Pharma (KAPA) has a FCF Yield % of -45.79 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #1177 out of 1415 companies in the Biotechnology industry, placing it in the top 83.2%.
Is Kairos Pharma's FCF Yield % too high?
Kairos Pharma's current FCF Yield % is -45.79. Based on the distribution chart, Kairos Pharma ranks #1177 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's FCF Yield % compare to IMNN and HCWB?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #1177 out of 1415 companies for FCF Yield %. This places Kairos Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Kairos Pharma and its competitors. Kairos Pharma's current FCF Yield % is -45.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current FCF Yield % of -45.79. The current FCF Yield % is -45.79. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current FCF Yield % is -45.79 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score
Get the complete analysis for KAPA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAPA has been successfully added to your 
